Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

GKOS vs DBVT

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
GKOS
Glaukos Corporation

Medical - Devices

HealthcareNYSE • US
Market Cap$7.81B
5Y Perf.+242.5%
DBVT
DBV Technologies S.A.

Biotechnology

HealthcareNASDAQ • FR
Market Cap$1690.08T
5Y Perf.-59.3%

GKOS vs DBVT — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
GKOS logoGKOS
DBVT logoDBVT
IndustryMedical - DevicesBiotechnology
Market Cap$7.81B$1690.08T
Revenue (TTM)$551M$0.00
Net Income (TTM)$-189M$-168M
Gross Margin78.1%
Operating Margin-15.6%
Total Debt$140M$22M
Cash & Equiv.$91M$194M

GKOS vs DBVTLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

GKOS
DBVT
StockMay 20May 26Return
Glaukos Corporation (GKOS)100342.5+242.5%
DBV Technologies S.… (DBVT)10040.7-59.3%

Price return only. Dividends and distributions are not included.

Quick Verdict: GKOS vs DBVT

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: GKOS leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. DBV Technologies S.A. is the stronger pick specifically for profitability and margin quality and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
GKOS
Glaukos Corporation
The Income Pick

GKOS carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • beta 1.16
  • Rev growth 32.3%, EPS growth -18.4%, 3Y rev CAGR 21.5%
  • 454.5% 10Y total return vs DBVT's -87.1%
Best for: income & stability and growth exposure
DBVT
DBV Technologies S.A.
The Quality Compounder

DBVT is the clearest fit if your priority is quality and momentum.

  • 0.3% margin vs GKOS's -34.3%
  • +100.5% vs GKOS's +47.5%
Best for: quality and momentum
See the full category breakdown
CategoryWinnerWhy
GrowthGKOS logoGKOS32.3% revenue growth vs DBVT's -100.0%
Quality / MarginsDBVT logoDBVT0.3% margin vs GKOS's -34.3%
Stability / SafetyGKOS logoGKOSBeta 1.16 vs DBVT's 1.26
DividendsTieNeither stock pays a meaningful dividend
Momentum (1Y)DBVT logoDBVT+100.5% vs GKOS's +47.5%
Efficiency (ROA)GKOS logoGKOS-20.1% ROA vs DBVT's -89.0%

GKOS vs DBVT — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

GKOSGlaukos Corporation
FY 2019
Glaucoma
97.5%$231M
Corneal Health
2.5%$6M
DBVTDBV Technologies S.A.

Segment breakdown not available.

GKOS vs DBVT — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLGKOSLAGGINGDBVT

Income & Cash Flow (Last 12 Months)

DBVT leads this category, winning 1 of 1 comparable metric.

GKOS and DBVT operate at a comparable scale, with $551M and $0 in trailing revenue.

MetricGKOS logoGKOSGlaukos Corporati…DBVT logoDBVTDBV Technologies …
RevenueTrailing 12 months$551M$0
EBITDAEarnings before interest/tax-$40M-$112M
Net IncomeAfter-tax profit-$189M-$168M
Free Cash FlowCash after capex-$18M-$151M
Gross MarginGross profit ÷ Revenue+78.1%
Operating MarginEBIT ÷ Revenue-15.6%
Net MarginNet income ÷ Revenue-34.3%
FCF MarginFCF ÷ Revenue-3.4%
Rev. Growth (YoY)Latest quarter vs prior year+41.2%
EPS Growth (YoY)Latest quarter vs prior year-6.3%+91.5%
DBVT leads this category, winning 1 of 1 comparable metric.

Valuation Metrics

Evenly matched — GKOS and DBVT each lead in 1 of 2 comparable metrics.
MetricGKOS logoGKOSGlaukos Corporati…DBVT logoDBVTDBV Technologies …
Market CapShares × price$7.8B$1690.08T
Enterprise ValueMkt cap + debt − cash$7.9B$1690.08T
Trailing P/EPrice ÷ TTM EPS-40.71x-0.75x
Forward P/EPrice ÷ next-FY EPS est.
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple
Price / SalesMarket cap ÷ Revenue15.40x
Price / BookPrice ÷ Book value/share11.64x0.65x
Price / FCFMarket cap ÷ FCF
Evenly matched — GKOS and DBVT each lead in 1 of 2 comparable metrics.

Profitability & Efficiency

Evenly matched — GKOS and DBVT each lead in 4 of 8 comparable metrics.

GKOS delivers a -26.5% return on equity — every $100 of shareholder capital generates $-26 in annual profit, vs $-130 for DBVT. DBVT carries lower financial leverage with a 0.13x debt-to-equity ratio, signaling a more conservative balance sheet compared to GKOS's 0.21x. On the Piotroski fundamental quality scale (0–9), DBVT scores 4/9 vs GKOS's 3/9, reflecting mixed financial health.

MetricGKOS logoGKOSGlaukos Corporati…DBVT logoDBVTDBV Technologies …
ROE (TTM)Return on equity-26.5%-130.2%
ROA (TTM)Return on assets-20.1%-89.0%
ROICReturn on invested capital-9.2%
ROCEReturn on capital employed-10.3%-145.7%
Piotroski ScoreFundamental quality 0–934
Debt / EquityFinancial leverage0.21x0.13x
Net DebtTotal debt minus cash$49M-$172M
Cash & Equiv.Liquid assets$91M$194M
Total DebtShort + long-term debt$140M$22M
Interest CoverageEBIT ÷ Interest expense-18.69x-189.82x
Evenly matched — GKOS and DBVT each lead in 4 of 8 comparable metrics.

Total Returns (Dividends Reinvested)

GKOS leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in GKOS five years ago would be worth $17,474 today (with dividends reinvested), compared to $3,172 for DBVT. Over the past 12 months, DBVT leads with a +100.5% total return vs GKOS's +47.5%. The 3-year compound annual growth rate (CAGR) favors GKOS at 31.5% vs DBVT's 5.7% — a key indicator of consistent wealth creation.

MetricGKOS logoGKOSGlaukos Corporati…DBVT logoDBVTDBV Technologies …
YTD ReturnYear-to-date+20.6%+3.6%
1-Year ReturnPast 12 months+47.5%+100.5%
3-Year ReturnCumulative with dividends+127.6%+18.1%
5-Year ReturnCumulative with dividends+74.7%-68.3%
10-Year ReturnCumulative with dividends+454.5%-87.1%
CAGR (3Y)Annualised 3-year return+31.5%+5.7%
GKOS leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

GKOS leads this category, winning 2 of 2 comparable metrics.

GKOS is the less volatile stock with a 1.16 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. GKOS currently trades 91.0% from its 52-week high vs DBVT's 75.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricGKOS logoGKOSGlaukos Corporati…DBVT logoDBVTDBV Technologies …
Beta (5Y)Sensitivity to S&P 5001.16x1.26x
52-Week HighHighest price in past year$146.75$26.18
52-Week LowLowest price in past year$73.16$7.53
% of 52W HighCurrent price vs 52-week peak+91.0%+75.3%
RSI (14)Momentum oscillator 0–10061.547.4
Avg Volume (50D)Average daily shares traded674K252K
GKOS leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Wall Street rates GKOS as "Buy" and DBVT as "Buy". Consensus price targets imply 134.8% upside for DBVT (target: $46) vs 9.8% for GKOS (target: $147).

MetricGKOS logoGKOSGlaukos Corporati…DBVT logoDBVTDBV Technologies …
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$146.67$46.33
# AnalystsCovering analysts2415
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises0
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

GKOS leads in 2 of 6 categories (Total Returns, Risk & Volatility). DBVT leads in 1 (Income & Cash Flow). 2 tied.

Best OverallGlaukos Corporation (GKOS)Leads 2 of 6 categories
Loading custom metrics...

GKOS vs DBVT: Frequently Asked Questions

8 questions · data-driven answers · updated daily

01

Is GKOS or DBVT a better buy right now?

Analysts rate Glaukos Corporation (GKOS) a "Buy" — based on 24 analyst ratings — the highest consensus in this comparison.

The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — GKOS or DBVT?

Over the past 5 years, Glaukos Corporation (GKOS) delivered a total return of +74.

7%, compared to -68. 3% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: GKOS returned +454. 5% versus DBVT's -87. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — GKOS or DBVT?

By beta (market sensitivity over 5 years), Glaukos Corporation (GKOS) is the lower-risk stock at 1.

16β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 9% more volatile than GKOS relative to the S&P 500. On balance sheet safety, DBV Technologies S. A. (DBVT) carries a lower debt/equity ratio of 13% versus 21% for Glaukos Corporation — giving it more financial flexibility in a downturn.

04

Which is growing faster — GKOS or DBVT?

On earnings-per-share growth, the picture is similar: Glaukos Corporation grew EPS -18.

4% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — GKOS or DBVT?

DBV Technologies S.

A. (DBVT) is the more profitable company, earning 0. 0% net margin versus -37. 0% for Glaukos Corporation — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DBVT leads at 0. 0% versus -17. 1% for GKOS. At the gross margin level — before operating expenses — GKOS leads at 77. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Which pays a better dividend — GKOS or DBVT?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

07

Is GKOS or DBVT better for a retirement portfolio?

For long-horizon retirement investors, Glaukos Corporation (GKOS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

16), +454. 5% 10Y return). Both have compounded well over 10 years (GKOS: +454. 5%, DBVT: -87. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

08

What are the main differences between GKOS and DBVT?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: GKOS is a small-cap high-growth stock; DBVT is a mega-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

GKOS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 20%
  • Gross Margin > 46%
Run This Screen
Stocks Like

DBVT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.